Foreword: Special Topics in Clinical Monitoring (sponsor DoD Hearing Center of Excellence; Pharmaceutical Interventions for Hearing Loss Group).
Foreword: Special Topics in Clinical Monitoring (sponsor DoD Hearing Center of Excellence; Pharmaceutical Interventions for Hearing Loss Group).
复制标题
前言：临床监测专题（主办机构：国防部听力卓越中心；听力损失药物干预小组）。
DOI：
10.1080/14992027.2018.1495816
复制
发表时间：
2018
影响因子：
2.7
通讯作者：
Watts,Kelly
中科院分区：
文献类型：
--
作者：
Boudin-George,Amy;Brewer,Carmen;Watts,Kelly
《国际听力学杂志》（IJA）的增刊“耳毒性——临床监测专题”是由美国国防部（DoD）听力卓越中心（HCE）成立的一个工作组出版的。HCE致力于为服务人员和退伍军人预防、诊断、缓解、治疗和康复听力损失和听庭系统损伤。HCE成立了听力损失药物干预（PIHL）工作组，以便国防部、退伍军人事务部（VA）、国家耳聋和沟通障碍研究所（NIDCD）和其他联邦机构的利益可以与学术界和工业界的利益结合起来。在认识到国防部和退伍军人事务部以及私营部门的耳毒性监测方案和方案需要更加标准化之后，成立了耳毒性监测小组委员会。耳毒性监测小组委员会是PIHL耳毒性委员会的一个分支机构，主要关注药物和/或电离辐射引起的耳毒性的临床问题和解决方案。听力学界早就知道，监测药物引起的耳毒性有助于改善或解决治疗方案后患者的听觉和前庭预后。尽管存在为监测方案提供信息的指导（ASHA 1994; AAA 2009），但这些文件更多地与具体的测试和报告方案相一致，而不是与制定成功规划的战略相一致。耳毒性监测计划（OMP）后勤设计、向利益相关者宣传听力学监测的价值和重要性，以及向患者和患者护理团队传达重要发现和建议等相关因素，如果在规划阶段不考虑这些问题，可能会使计划难以启动。
This supplemental edition of the International Journal of Audiology (IJA),“Ototoxicity–Special Topics in Clinical Monitoring,” came about via a working group established by the United States Department of Defense (DoD) Hearing Center of Excellence (HCE). The HCE is dedicated to focussing on initiatives regarding the prevention, diagnosis, mitigation, treatment, and rehabilitation of hearing loss and auditory-vestibular system injury for Service members and Veterans. The HCE formed the Pharmaceutical Interventions for Hearing Loss (PIHL) Working Group so that interests from the DoD, Department of Veterans Affairs (VA), the National Institute on Deafness and Communication Disorders (NIDCD), and other federal agencies could be joined with those of academia and industry. An Ototoxicity Monitoring Subcommittee was formed after recognising the need for more standardisation in ototoxicity monitoring protocols and programmes in the DoD and VA, as well as in the private sector. The Ototoxicity Monitoring Subcommittee, a subset of the PIHL Ototoxicity Committee, focuses primarily on clinical issues and solutions to ototoxicity caused by pharmaceuticals and/or ionising radiation.The audiology community has long known that monitoring for medication-induced ototoxicity is helpful in improving or addressing patients auditory and vestibular outcomes subsequent to therapeutic treatment protocols. Though guidance exists to inform monitoring protocols (ASHA 1994; AAA 2009), these documents align more with specific testing and reporting protocols than with strategies to develop successful programmes. Factors related to design of ototoxicity monitoring programmes (OMP) logistics, promotion of the value and importance of audiologic monitoring to stakeholders, as well as communication of significant findings and recommendations to the patient and patient care team may make it difficult to get a programme off the ground if these issues are not considered in the planning stages.